Genetic Signatures is governed by a Board of Directors who oversee the integrity of our business operations.
Members of our Board include:
Anne Lockwood
Non-Executive Director
Mrs Lockwood has over 30 years’ experience in various finance, risk management and audit roles including deep experience in mergers and acquisitions across a range of industries. Mrs Lockwood is the former Chief Financial and Commercial Officer of ASX-listed Integral Diagnostics (ASX: IDX) and is the former the Chief Financial Officer of privately owned Planet Innovation, and Non-Executive Director of Mayne Pharma Group Limited. Mrs Lockwood has spent over 20 years in accounting and audit roles including 18 years at Arthur Andersen and Ernst Young. Anne holds a Bachelor of Commerce degree with majors in accounting and law, is a chartered accountant, a fellow of the Institute of Chartered Accountants and a graduate of the Australian Institute of Company Directors.
Dr Jenny Harry
Non-Executive Director
Dr Jenny Harry has had 25 years’ experience in executive roles and as an independent Director in leading early-stage companies to develop and commercialise innovative products. She co-founded Proteome Systems Limited with the team who pioneered the scientific field of proteomics and commercialised a suite of disruptive technologies including reagents, instrumentation and software in Australia, the USA and Japan. As CEO of Tyrian Diagnostics Ltd she secured agreements with multi-national companies for the development and commercialisation of agricultural and clinical diagnostic products.
Jenny has served on the Boards of companies in the technology, pharmaceutical and creative industries. She is a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX:NEU) and Aeris Environmental Ltd (ASX:AEI). She joined the Neuren Board in 2018. During the ensuing 6-year period, the Company has achieved enterprise growth from $170m to ~$2B and in 2023 the Company was elevated to the ASX200 index.
Jenny holds a PhD in developmental biology, and is a graduate of the Harvard Business School’s General Management Program and the Australian Institute of Company Directors.
Dr Neil Gunn
Non-Executive Director (Interim Chief Executive Officer)
Dr Neil Gunn has over 30 years experience in medical devices and diagnostics. Until recently, Dr Gunn was President of Roche Sequencing Solutions (RSS), where he oversaw all aspects of the business and managed a team of ~ 900 people.
While much of the Roche sequencing business is in the product development phase his team developed and launched over 20 products a year as part of the clinical workflow, analysis software or assays run on commercially available sequencers. Prior to his role with RSS, Dr Gunn held the position of Vice President in Roche’s Molecular Diagnostic business unit. During this twelve-year tenure, he was responsible for over 120 diagnostic product launches (instruments, assays, software) with a principle focus on IVD clinical markets.
Read More
Mike Aicher
BSc, MBA. Executive Director – U.S. Operations
Mr Aicher has over 30 years of industry experience, and was CEO and founder of National Genetics Institute (NGI) and acquired by Laboratory Corporation of America, Inc. (LabCorp) in 2000.
More recently, Mr. Aicher led LabCorp’s Western Division and was previously responsible for the Company’s Esoteric Business Units, which generated more than $1 billion in annual revenue.
More recently, Mr. Aicher led LabCorp’s Western Division and was previously responsible for the Company’s Esoteric Business Units, which generated more than $1 billion in annual revenue.
Prior to NGI, Mr. Aicher served in a number of executive leadership roles at Central Diagnostics Laboratory.
He currently serves as a director on boards of Ariosa Diagnostics, Inc. and Omicia, Inc. He is certified by the University of California at Berkeley as a Global Biotechnology Executive and is a recipient of Ernst & Young’s “Entrepreneur of the Year” award for emerging technologies. Mr Aicher received a B.S. in Business Administration from the University of Redlands and an M.B.A. in Economics from Columbus University.
Read More
He currently serves as a director on boards of Ariosa Diagnostics, Inc. and Omicia, Inc. He is certified by the University of California at Berkeley as a Global Biotechnology Executive and is a recipient of Ernst & Young’s “Entrepreneur of the Year” award for emerging technologies. Mr Aicher received a B.S. in Business Administration from the University of Redlands and an M.B.A. in Economics from Columbus University.
Caroline Waldron
CHAIR
Caroline Waldron brings unique skills and experience to Genetic Signatures including leadership roles in law, human resources, marketing, risk, and internal auditing, gained from ASX100 and Bluechip organisations. Ms Waldron’s formal training is in law and she has been admitted to the Bar of England and Wales, and the courts of various jurisdictions including in Australia and New Zealand.
Ms Waldron’s 30+ years of international and ASX executive experience across multiple sectors support strategic decision making to drive company growth and shareholder value. She has led organisational culture rebuild initiatives and advises offshore developers and funds on investment opportunities. Ms Waldron is currently a Director of Resimac Group Limited (ASX:RMC) and AMA Group Limited (ASX:AMA).
Read More
